#BEGIN_DRUGCARD DB03256

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
58-05-9

# ChEBI_ID:
15640

# Chemical_Formula:
C20H23N7O7

# Chemical_IUPAC_Name:
(2R)-2-{[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]formamido}pentanedioic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
The active metabolite of FOLIC ACID. Leucovorin is used principally as its calcium salt as an antidote to folic acid antagonists which block the conversion of folic acid to folinic acid. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Vitamin B Complex

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
5-Formyl-5,6,7,8-Tetrahydrofolate

# HET_ID:
FON

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12-,13+/m0/s1

# InChI_Key:
InChIKey=VVIAGPKUTFNRDU-QWHCGFSZSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C03479

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3256

# Mechanism_Of_Action:
Not Available

# Melting_Point:
245 dec Â°C

# Molecular_Weight_Avg:
473.4393

# Molecular_Weight_Mono:
473.165896125

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1KL2

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.1

# Predicted_LogS:
-3.2

# Predicted_Water_Solubility:
3.00e-01 g/l

# Primary_Accession_No:
DB03256

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
3033683

# PubChem_Substance_ID:
46506235

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01470

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@H](CCC(O)=O)C(O)=O)N2C=O)N1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:04 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
Not Available

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AF329477

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
dmg

# Drug_Target_1_Gene_Sequence:
>2493 bp
ATGGCATCGACGCCGCGTATTGTCATTATTGGAGCCGGCATTGTCGGTACGAACCTGGCC
GACGAGCTGGTCACCCGGGGCTGGAATAACATCACTGTCCTGGACCAGGGGCCTTTGAAT
ATGCCCGGCGGGTCCACGTCCCATGCCCCGGGCCTGGTTTTCCAGACCAACCCGTCCAAG
ACCATGGCCTCTTTCGCCAAGTACACGGTGGAGAAGCTGCTGTCGCTGACCGAGGACGGG
GTGAGCTGCTTCAACCAGGTCGGTGGCCTGGAAGTGGCCACCACCGAAACCCGCCTCGCT
GACCTGAAGCGCAAACTCGGCTACGCCGCCGCCTGGGGCATCGAAGGGCGCCTCCTGTCC
CCGGCCGAGTGCCAGGAGCTGTACCCGCTCCTGGACGGGGAAAACATCCTGGGCGGCCTC
CACGTGCCCAGCGATGGCCTGGCCAGCGCCGCCCGTGCGGTGCAGCTGCTGATCAAACGC
ACCGAGTCCGCCGGGGTCACATACCGCGGTTCGACCACCGTGACGGGCATTGAGCAGTCC
GGAGGCCGTGTCACGGGCGTGCAGACCGCCGACGGCGTGATCCCGGCCGATATCGTGGTG
TCCTGCGCCGGGTTCTGGGGCGCGAAGATCGGGGCCATGATCGGCATGGCCGTTCCCCTG
CTCCCGCTGGCCCACCAGTACGTAAAAACCACCCCGGTACCGGCGCAGCAGGGCAGGAAC
GACCAGCCGAACGGGGCCCGGCTGCCGATCCTGCGCCACCAGGACCAGGACCTCTACTAC
CGCGAACACGGGGACCGGTACGGCATCGGCTCCTACGCCCACCGGCCCATGCCCGTGGAC
GTCGACACCCTGGGGGCCTACGCGCCCGAGACCGTCAGCGAACACCACATGCCCTCCCGC
CTCGACTTCACCCTGGAGGACTTCCTGCCGGCGTGGGAGGCCACCAAGCAGCTCCTGCCC
GCGCTGGCGGACAGCGAGATCGAGGACGGCTTCAACGGCATCTTCTCCTTCACCCCCGAC
GGCGGGCCGCTCCTTGGCGAATCCAAGGAACTCGACGGCTTCTACGTCGCCGAAGCCGTC
TGGGTCACGCACTCCGCCGGCGTGGCCAAGGCCATGGCCGAACTGCTGACCACCGGCCGG
TCCGAGACCGACCTGGGCGAGTGCGACATCACCCGCTTCGAGGACGTCCAGCTCACCCCC
GAATACGTCAGCGAAACCTCACAGCAGAACTTCGTGGAAATCTACGACGTCCTGCACCCG
CTCCAGCCCAGACTCTCCCCCCGCAACCTGCGCGTGAGCCCCTTCCACGCCCGGCACAAA
GAACTCGGCGCGTTCTTCCTGGAAGCCGGCGGCTGGGAACGGCCCTACTGGTTCGAAGCC
AACGCCGCACTCCTCAAGGAGATGCCGGCCGAGTGGCTGCCGCCCGCACGCGACGCCTGG
TCCGGAATGTTCAGCTCCCCGATCGCCGCCGCCGAAGCCTGGAAAACCCGCACGGCCGTA
GCCATGTACGACATGACCCCGCTCAAGCGCCTCGAGGTCTCCGGCCCGGGGGCCCTCAAG
CTCCTGCAGGAACTGACGACGGCGGACCTGGCCAAGAAGCCGGGCGCGGTCACCTACACC
CTGCTGCTCGACCACGCCGGCGGCGTGCGAAGCGACATCACGGTGGCCCGCCTGAGCGAG
GACACCTTCCAGCTCGGCGCCAACGGCAACATCGACACCGCCTACTTCGAGCGGGCGGCC
CGGCACCAGACGCAAAGCGGATCCGCCACCGACTGGGTCCAGGTGCGCGACACCACCGGC
GGCACCTGCTGCATCGGCCTCTGGGGCCCGCTCGCCCGGGACCTCGTCAGCAAAGTCAGC
GACGACGACTTCACCAACGACGGCCTGAAGTACTTCCGGGCCAAGAACGTCGTCATCGGC
GGCATTCCCGTTACCGCCATGCGGCTTTCCTACGTCGGTGAACTCGGCTGGGAGCTGTAC
ACCAGCGCCGACAACGGACAGCGGCTGTGGGATGCGCTCTGGCAGGCAGGACAGCCCTTC
GGAGTCATCGCCGCCGGACGCGCGGCATTCAGCTCCCTGCGGCTCGAAAAGGGCTACCGC
TCCTGGGGAACCGACATGACCACGGAGCACGACCCCTTCGAAGCAGGGCTCGGATTCGCC
GTCAAGATGGCCAAGGAGAGCTTCATCGGCAAGGGCGCGCTCGAAGGCCGGACCGAAGAG
GCCTCCGCCCGCCGGCTGCGCTGCCTGACCATCGACGACGGCCGGTCCATCGTCCTCGGC
AAGGAACCCGTCTTCTACAAGGAACAGGCCGTCGGCTACGTCACCAGCGCCGCCTACGGG
TACACCGTGGCCAAACCCATCGCCTACTCCTACCTGCCGGGCACCGTCTCGGTCGGCGAC
TCCGTCGACATCGAATACTTCGGACGGCGCATCACCGCCACCGTCACAGAAGACCCGCTG
TACGACCCGAAAATGACCAGGCTCCGCGGCTAA

# Drug_Target_1_General_Function:
Involved in oxidoreductase activity

# Drug_Target_1_General_References:
11422368	Meskys R, Harris RJ, Casaite V, Basran J, Scrutton NS: Organization of the genes involved in dimethylglycine and sarcosine degradation in Arthrobacter spp.: implications for glycine betaine catabolism. Eur J Biochem. 2001 Jun;268(12):3390-8.
12912903	Leys D, Basran J, Scrutton NS: Channelling and formation of 'active' formaldehyde in dimethylglycine oxidase. EMBO J. 2003 Aug 15;22(16):4038-48.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
5072

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
89986

# Drug_Target_1_Name:
N,N-dimethylglycine oxidase

# Drug_Target_1_Number_of_Residues:
830

# Drug_Target_1_PDB_ID:
1PJ7

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01266	DAO
PF01571	GCV_T

# Drug_Target_1_Protein_Sequence:
>N,N-dimethylglycine oxidase
MASTPRIVIIGAGIVGTNLADELVTRGWNNITVLDQGPLNMPGGSTSHAPGLVFQTNPSK
TMASFAKYTVEKLLSLTEDGVSCFNQVGGLEVATTETRLADLKRKLGYAAAWGIEGRLLS
PAECQELYPLLDGENILGGLHVPSDGLASAARAVQLLIKRTESAGVTYRGSTTVTGIEQS
GGRVTGVQTADGVIPADIVVSCAGFWGAKIGAMIGMAVPLLPLAHQYVKTTPVPAQQGRN
DQPNGARLPILRHQDQDLYYREHGDRYGIGSYAHRPMPVDVDTLGAYAPETVSEHHMPSR
LDFTLEDFLPAWEATKQLLPALADSEIEDGFNGIFSFTPDGGPLLGESKELDGFYVAEAV
WVTHSAGVAKAMAELLTTGRSETDLGECDITRFEDVQLTPEYVSETSQQNFVEIYDVLHP
LQPRLSPRNLRVSPFHARHKELGAFFLEAGGWERPYWFEANAALLKEMPAEWLPPARDAW
SGMFSSPIAAAEAWKTRTAVAMYDMTPLKRLEVSGPGALKLLQELTTADLAKKPGAVTYT
LLLDHAGGVRSDITVARLSEDTFQLGANGNIDTAYFERAARHQTQSGSATDWVQVRDTTG
GTCCIGLWGPLARDLVSKVSDDDFTNDGLKYFRAKNVVIGGIPVTAMRLSYVGELGWELY
TSADNGQRLWDALWQAGQPFGVIAAGRAAFSSLRLEKGYRSWGTDMTTEHDPFEAGLGFA
VKMAKESFIGKGALEGRTEEASARRLRCLTIDDGRSIVLGKEPVFYKEQAVGYVTSAAYG
YTVAKPIAYSYLPGTVSVGDSVDIEYFGRRITATVTEDPLYDPKMTRLRG

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q9AGP8

# Drug_Target_1_SwissProt_Name:
Q9AGP8_ARTGO

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
5.00

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
BA000043

# Drug_Target_2_GenBank_ID_Protein:
56381746

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
glyA

# Drug_Target_2_Gene_Sequence:
>1239 bp
TTAGTCTTGATAGAGCGGAAACTTTTCCGTCAAAGCGGCGACGCGTTGGCGCGCTTCCTC
AAGCGCTTGTTCGCTGCCGACGTTTTTCAGCACAAGGCCGATGATGGCGGCGATTTCGTC
CATCTCTTCCAATCCGAAGCCGCGCGTCGTGACCGCGGCCGTGCCGATGCGGATGCCGCT
TGTGACAAACGGGCTTTCCGGATCGTACGGAATCGTGTTTTTGTTGACCGTAATCCCGAC
CTCATCGAGCACTTTCTCCGCCGTTTTCCCGGTCAGCTGCTGCGGGCGCAAATCGACAAG
CAGCAAATGGTTGTCCGTGCCGCCGGAAATGAGAGTGAATCCTTCGTTTTGCAAGGCGGC
TGCGAGCCGTTTGGCATTCTCCACGACGCGCTTCGCGTAGACTTTAAAGTCGTCTTGCAA
CGCTTCGCCGAGCGCGACGGCTTTGGCGGCAATGACATGCATGAGCGGGCCGCCTTGAAT
GCCAGGGAAAATGGCTTTGTCGATCTGTTTGGCGAACTGCTCCTGGCATAAAATCATCCC
GCCGCGCGGACCGCGCAGCGTTTTGTGCGTCGTCGTCGTAACGAAATGGGCGTACGGCAC
TGGATTCGGATGAACACCTGCCGCAACAAGACCGGCAATATGGGCCATGTCAACCATTAA
ATAGGCGCCGACTTCATCGGCAATCTCGCGGAACTTGGCGAAGTCGATGATGCGCGGATA
GGCGCTCGCGCCGGCGACGATCAACTTCGGCCGGTGAAGGCGCGCTTTTTCGCGCACGTC
GTCATAGTCAATGACATGCGTTTCCGGATCGACGCCGTATTCGACAAAATTGTACTGAAT
GCCGCTGAAATTGACCGGGCTGCCGTGCGTCAAATGGCCGCCGTGCGACAAGTTCATGCC
AAGCACCGTGTCGCCGTGCTCAAGAACGGTGAAATAAACGGCCATGTTCGCCTGCGCCCC
GGAGTGCGGCTGGACGTTCACATGCTCCGCTCCAAACAACTGCTTCGCTCGCTCGCGCGC
CAAATCTTCGACGATGTCGACATATTCACAACCGCCGTAGTAGCGGCGTCCCGGATAGCC
TTCCGCATATTTGTTCGTCAGCACCGACCCTTGCGCTTCCATGACCGCGCGGCTGACAAA
GTTTTCCGAGGCGATCAGTTCAATTTTCGCATGTTGCCGCTTCCGCTCTTGCTCAATAGC
GGCGAACACTTGCGGATCTTGTTGTGGCAAGTAATTCAT

# Drug_Target_2_General_Function:
Amino acid transport and metabolism

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3193

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
45176

# Drug_Target_2_Name:
Serine hydroxymethyltransferase

# Drug_Target_2_Number_of_Residues:
412

# Drug_Target_2_PDB_ID:
1KL2

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00464	SHMT

# Drug_Target_2_Protein_Sequence:
>Serine hydroxymethyltransferase
MNYLPQQDPQVFAAIEQERKRQHAKIELIASENFVSRAVMEAQGSVLTNKYAEGYPGRRY
YGGCEYVDIVEDLARERAKQLFGAEHVNVQPHSGAQANMAVYFTVLEHGDTVLGMNLSHG
GHLTHGSPVNFSGIQYNFVEYGVDPETHVIDYDDVREKARLHRPKLIVAGASAYPRIIDF
AKFREIADEVGAYLMVDMAHIAGLVAAGVHPNPVPYAHFVTTTTHKTLRGPRGGMILCQE
QFAKQIDKAIFPGIQGGPLMHVIAAKAVALGEALQDDFKVYAKRVVENAKRLAAALQNEG
FTLISGGTDNHLLLVDLRPQQLTGKTAEKVLDEVGITVNKNTIPYDPESPFVTSGIRIGT
AAVTTRGFGLEEMDEIAAIIGLVLKNVGSEQALEEARQRVAALTEKFPLYQD

# Drug_Target_2_Reaction:
5,10-methylenetetrahydrofolate + glycine + H2O = tetrahydrofolate + L-serine

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Interconversion of serine and glycine

# Drug_Target_2_SwissProt_ID:
Q5KUI2

# Drug_Target_2_SwissProt_Name:
GLYA_GEOKA

# Drug_Target_2_Synonyms:
EC 2.1.2.1
SHMT
Serine methylase

# Drug_Target_2_Theoretical_pI:
6.24

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
AE000512

# Drug_Target_3_GenBank_ID_Protein:
4980708

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
gcvT

# Drug_Target_3_Gene_Sequence:
>1095 bp
ATGAAGAGAACGCCTCTATTTGAAAAGCATGTTGAACTCGGTGCGAAAATGGTAGATTTC
GCGGGGTGGGAGATGCCTCTTTATTACACATCCATATTCGAAGAAGTGATGGCAGTCAGA
AAATCGGTGGGGATGTTCGATGTCTCTCACATGGGGGAATTTCTCGTTAAAGGGCCCGAG
GCGGTTTCTTTTATTGACTTTCTTATAACGAACGACTTTTCTTCACTTCCGGATGGTAAA
GCGATTTACTCTGTCATGTGCAATGAAAACGGTGGAATCATCGATGATCTTGTTGTGTAC
AAGGTGAGTCCTGATGAAGCTCTCATGGTGGTGAACGCGGCAAACATTGAAAAGGACTTC
AACTGGATAAAATCCCATTCGAAGAATTTCGATGTCGAAGTATCGAACATTTCAGATACG
ACAGCGCTCATAGCGTTCCAGGGGCCAAAAGCACAGGAGACCCTCCAGGAGCTTGTTGAA
GACGGTCTCGAGGAAATTGCCTATTATTCTTTCAGAAAGAGTATTGTAGCCGGTGTAGAG
ACTCTTGTCTCAAGAACGGGATACACGGGTGAGGACGGTTTCGAACTGATGCTTGAAGCG
AAGAATGCACCGAAGGTCTGGGATGCTTTGATGAATCTGCTCAGAAAAATCGATGGCAGA
CCCGCAGGTCTTGGGGCGAGAGACGTTTGCCGACTCGAGGCGACTTATTTGCTGTACGGT
CAGGACATGGATGAGAACACGAATCCTTTCGAAGTGGGACTTTCCTGGGTTGTAAAACTG
AACAAAGACTTCGTGGGGAAGGAAGCGCTGCTGAAAGCGAAGGAAAAAGTGGAAAGAAAA
CTTGTGGCGCTTGAGCTCTCTGGAAAAAGAATAGCAAGAAAAGGCTATGAAGTTTTAAAG
AATGGAGAGAGAGTGGGAGAGATCACAAGTGGTAACTTCTCTCCAACTCTTGGGAAGTCG
ATAGCGCTGGCTCTCGTTTCAAAATCGGTGAAGATAGGAGACCAACTGGGAGTGGTGTTT
CCTGGTGGAAAGCTTGTAGAAGCTCTGGTAGTAAAAAAACCATTTTACAGAGGCAGTGTG
AGGAGGGAGGTTTGA

# Drug_Target_3_General_Function:
Amino acid transport and metabolism

# Drug_Target_3_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
3082

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
40333

# Drug_Target_3_Name:
Aminomethyltransferase

# Drug_Target_3_Number_of_Residues:
364

# Drug_Target_3_PDB_ID:
1WOS

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF01571	GCV_T
PF08669	GCV_T_C

# Drug_Target_3_Protein_Sequence:
>Aminomethyltransferase
MKRTPLFEKHVELGAKMVDFAGWEMPLYYTSIFEEVMAVRKSVGMFDVSHMGEFLVKGPE
AVSFIDFLITNDFSSLPDGKAIYSVMCNENGGIIDDLVVYKVSPDEALMVVNAANIEKDF
NWIKSHSKNFDVEVSNISDTTALIAFQGPKAQETLQELVEDGLEEIAYYSFRKSIVAGVE
TLVSRTGYTGEDGFELMLEAKNAPKVWDALMNLLRKIDGRPAGLGARDVCRLEATYLLYG
QDMDENTNPFEVGLSWVVKLNKDFVGKEALLKAKEKVERKLVALELSGKRIARKGYEVLK
NGERVGEITSGNFSPTLGKSIALALVSKSVKIGDQLGVVFPGGKLVEALVVKKPFYRGSV
RREV

# Drug_Target_3_Reaction:
[protein]-S8-aminomethyldihydrolipoyllysine + tetrahydrofolate = [protein]-dihydrolipoyllysine + 5,10-methylenetetrahydrofolate + NH3

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
The glycine cleavage system catalyzes the degradation of glycine

# Drug_Target_3_SwissProt_ID:
Q9WY54

# Drug_Target_3_SwissProt_Name:
GCST_THEMA

# Drug_Target_3_Synonyms:
EC 2.1.2.10
Glycine cleavage system T protein

# Drug_Target_3_Theoretical_pI:
5.23

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
AY057445

# Drug_Target_4_GenBank_ID_Protein:
16555376

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
arnA

# Drug_Target_4_Gene_Sequence:
>1983 bp
ATGAAAACCGTCGTTTTTGCCTACCACGATATGGGATGCCTCGGTATTGAAGCCCTGCTG
GCTGCCGGTTACGAAATTAGCGCCATTTTTACCCATACTGATAATCCCGGTGAAAAAGCC
TTTTATGGTTCGGTGGCTCGTCTGGCGGCGGAAAGAGGCATTCCGGTTTATGCGCCGGAT
AACGTTAATCATCCGCTGTGGGTGGAACGCATTGCCCAACTGTCGCCAGATGTGATTTTC
TCTTTTTATTATCGCCATCTTATTTACGACGAAATTTTGCAGCTCGCTCCCGCAGGTGCA
TTTAATCTGCATGGTTCGCTGTTACCAAAATATCGTGGTCGCGCGCCGCTGAACTGGGTG
CTGGTCAACGGTGAAACGGAAACTGGCGTTACATTGCACCGAATGGTGAAACGTGCCGAT
GCCGGGGCCATTGTGGCGCAACTGCGCATTGCCATTGCGCCAGACGATATCGCTATTACG
CTGCATCATAAATTGTGCCATGCCGCGCGCCAGCTACTGGAACAGACATTACCCGCCATT
AAACACGGTAATATTCTGGAAATCGCCCAGCGCGAAAACGAAGCCACCTGTTTTGGTCGC
AGAACGCCGGATGACAGTTTCCTTGAATGGCATAAACCGGCATCCGTACTGCACAACATG
GTACGTGCCGTTGCCGATCCGTGGCCGGGTGCCTTCAGCTATGTTGGCAATCAGAAATTC
ACCGTCTGGTCGTCGCGTGTTCATCCTCATGCCAGCAAAGCACAGCCGGGGAGCGTGATT
TCTGTTGCGCCACTGCTGATTGCCTGTGGCGATGGCGCGCTGGAAATCGTCACCGGACAG
GCGGGCGACGGCATTACTATGCAGGGCTCGCAATTAGCGCAGACGCTGGGCCTGGTGCAA
GGTTCACGCTTGAATAGCCAGCCTGCCTGCACCGCCCGACGCCGTACCCGGGTACTCATC
CTCGGGGTGAATGGCTTTATTGGCAACCATCTGACAGAACGCCTGCTGCGCGAAGATCAT
TATGAAGTTTACGGTCTGGATATTGGCAGCGATGCGATAAGCCGTTTTCTGAATCATCCG
CATTTTCACTTTGTTGAAGGCGATATCAGTATTCATTCCGAATGGATTGAGTATCATGTC
AAAAAATGTGATGTCGTCTTGCCGCTGGTGGCGATAGCCACGCCGATTGAATATACCCGC
AACCCGCTGCGCGTATTTGAACTCGATTTTGAAGAGAATCTGCGCATTATCCGCTACTGC
GTGAAGTACCGTAAGCGAATCATCTTCCCGTCAACTTCAGAAGTTTATGGGATGTGTAGC
GATAAATACTTCGATGAGGACCATTCTAATTTAATCGTCGGCCCGGTGAATAAACCACGC
TGGATTTATTCGGTATCAAAACAATTACTTGATCGGGTGATCTGGGCCTATGGCGAAAAA
GAGGGTTTACAGTTCACCCTCTTCCGCCCGTTTAACTGGATGGGACCACGACTGGATAAC
CTTAATGCAGCGCGAATTGGCAGCTCCCGCGCTATTACGCAACTCATTCTCAATCTGGTA
GAAGGTTCACCGATTAAGCTGATTGATGGCGGAAAACAAAAACGCTGCTTTACTGATATT
CGCGATGGTATCGAGGCGTTATACCGCATTATCGAAAATGCGGGAAATCGCTGCGACGGT
GAAATTATCAACATTGGCAATCCTGAGAACGAAGCGAGCATTGAGGAACTGGGCGAGATG
CTGCTGGCGAGCTTCGAAAAACATCCGCTGCGCCATCATTTCCCACCGTTTGCGGGCTTT
CGCGTTGTCGAAAGTAGCAGCTACTACGGCAAAGGATATCAGGACGTAGAGCATCGTAAA
CCGAGCATCCGCAATGCCCACCGCTGCCTGGACTGGGAGCCGAAAATTGATATGCAGGAA
ACCATCGACGAAACGCTGGATTTCTTCCTGCGCACCGTTGATCTTACGGATAAACCATCA
TGA

# Drug_Target_4_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_4_General_References:
11706007	Breazeale SD, Ribeiro AA, Raetz CR: Oxidative decarboxylation of UDP-glucuronic acid in extracts of polymyxin-resistant Escherichia coli. Origin of lipid a species modified with 4-amino-4-deoxy-L-arabinose. J Biol Chem. 2002 Jan 25;277(4):2886-96. Epub 2001 Nov 8.
9205837	Yamamoto Y, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kimura S, Kitagawa M, Makino K, Miki T, Mitsuhashi N, Mizobuchi K, Mori H, Nakade S, Nakamura Y, Nashimoto H, Oshima T, Oyama S, Saito N, Sampei G, Satoh Y, Sivasundaram S, Tagami H, Horiuchi T, et al.: Construction of a contiguous 874-kb sequence of the Escherichia coli -K12 genome corresponding to 50.0-68.8 min on the linkage map and analysis of its sequence features. DNA Res. 1997 Apr 28;4(2):91-113.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
3257

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
74290

# Drug_Target_4_Name:
Bifunctional polymyxin resistance protein arnA

# Drug_Target_4_Number_of_Residues:
660

# Drug_Target_4_PDB_ID:
1U9J

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00551	Formyl_trans_N
PF01370	Epimerase
PF02911	Formyl_trans_C

# Drug_Target_4_Protein_Sequence:
>Bifunctional polymyxin resistance protein arnA
MKTVVFAYHDMGCLGIEALLAAGYEISAIFTHTDNPGEKAFYGSVARLAAERGIPVYAPD
NVNHPLWVERIAQLSPDVIFSFYYRHLIYDEILQLAPAGAFNLHGSLLPKYRGRAPLNWV
LVNGETETGVTLHRMVKRADAGAIVAQLRIAIAPDDIAITLHHKLCHAARQLLEQTLPAI
KHGNILEIAQRENEATCFGRRTPDDSFLEWHKPASVLHNMVRAVADPWPGAFSYVGNQKF
TVWSSRVHPHASKAQPGSVISVAPLLIACGDGALEIVTGQAGDGITMQGSQLAQTLGLVQ
GSRLNSQPACTARRRTRVLILGVNGFIGNHLTERLLREDHYEVYGLDIGSDAISRFLNHP
HFHFVEGDISIHSEWIEYHVKKCDVVLPLVAIATPIEYTRNPLRVFELDFEENLRIIRYC
VKYRKRIIFPSTSEVYGMCSDKYFDEDHSNLIVGPVNKPRWIYSVSKQLLDRVIWAYGEK
EGLQFTLFRPFNWMGPRLDNLNAARIGSSRAITQLILNLVEGSPIKLIDGGKQKRCFTDI
RDGIEALYRIIENAGNRCDGEIINIGNPENEASIEELGEMLLASFEKHPLRHHFPPFAGF
RVVESSSYYGKGYQDVEHRKPSIRNAHRCLDWEPKIDMQETIDETLDFFLRTVDLTDKPS

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Bifunctional enzyme that catalyzes the oxidative decarboxylation of UDP-glucuronic acid (UDP-GlcUA) to UDP-4-keto- arabinose (UDP-Ara4O) and the addition of a formyl group to UDP-4- amino-4-deoxy-L-arabinose (UDP-L-Ara4N) to form UDP-L-4-formamido- arabinose (UDP-L-Ara4FN). The modified arabinose is attached to lipid A and is required for resistance to polymyxin and cationic antimicrobial peptides

# Drug_Target_4_SwissProt_ID:
P77398

# Drug_Target_4_SwissProt_Name:
ARNA_ECOLI

# Drug_Target_4_Synonyms:
ArnAFT)
EC 1.1.1.-
EC 2.1.2.-
Polymyxin resistance protein pmrI
UDP-GlcUA decarboxylase
UDP-L-Ara4N formyltransferase
UDP-glucuronic acid dehydrogenase
UDP-glucuronic acid oxidase, UDP-4-keto-hexauronic acid decarboxylating

# Drug_Target_4_Theoretical_pI:
6.86

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Cytoplasm

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
FTCD

# Drug_Target_5_GenBank_ID_Gene:
AF169017

# Drug_Target_5_GenBank_ID_Protein:
6537208

# Drug_Target_5_GeneCard_ID:
FTCD

# Drug_Target_5_Gene_Name:
FTCD

# Drug_Target_5_Gene_Sequence:
>1626 bp
ATGTCCCAGCTGGTGGAATGCGTCCCCAACTTTTCGGAGGGGAAGAACCAGGAGGTGATC
GACGCCATCTCTGGAGCCATCACACAGACCCCGGGCTGCGTGCTGCTGGATGTGGACGCA
GGCCCTTCCACCAACCGCACCGTGTACACCTTCGTGGGGCCGCCGGAGTGCGTGGTGGAG
GGGGCCCTCAACGCTGCCCGGGTAGCTTCCCGACTTATCGACATGAGCAGGCACCAAGGA
GAGCACCCCCGCATGGGGGCCCTAGACGTCTGCCCCTTCATCCCCGTGAGGGGCGTCAGC
GTGGATGAGTGTGTGCTCTGCGCCCAGGCCTTTGGCCAGAGGCTGGCAGAGGAGCTGGAC
GTGCCAGTTTACCTGTACGGCGAGGCAGCCAGGATGGACAGTCGCCGGACCCTGCCGGCC
ATCCGGGCCGGGGAGTACGAGGCCCTCCCTAAGAAGCTCCAGCAGGCCGACTGGGCGCCC
GACTTTGGTCCCAGCTCCTTTGTCCCCAGTTGGGGGGCCACGGCCACGGGGGCGAGGAAG
TTCCTCATTGCTTTTAACATCAACCTGCTCGGCACAAAGGAGCAAGCCCACCGCATCGCG
CTCAACCTGCGGGAGCAGGGCCGCGGGAAGGACCAGCCAGGACGTCTGAAGAAAGTTCAG
GGCATTGGCTGGTACCTGGATGAGAAGAACCTGGCTCAGGTGTCCACCAATCTTCTGGAC
TTTGAGGTCACGGCACTGCACACGGTCTACGAGGAGACCTGCCGAGAAGCACAGGAGCTG
AGCCTCCCAGTGGTGGGCTCACAGCTGGTGGGCCTGGTGCCCCTGAAGGCTCTGCTGGAT
GCGGCCGCCTTCTACTGCGAGAAGGAGAACCTCTTCATCCTGGAGGAGGAGCAGCGGATC
AGGCTGGTGGTGAGCCGGCTGGGCCTGGACTCCCTGTGCCCCTTCAGCCCTAAGGAGCGG
ATCATCGAGTACCTGGTCCCTGAGCGCGGGCCTGAGCGAGGCCTGGGCAGCAAGTCCCTG
CGCGCCTTCGTGGGGGAGGTGGGTGCCCGCTCTGCGGCCCCCGGGGGCGGCTCGGTGGCG
GCGGCCGCTGCGGCCATGGGTGCGGCGCTGGGCTCCATGGTGGGCCTCATGACCTACGGG
CGGCGCCAATTCCAGTCCCTGGACACGACGATGCGGCGCCTGATCCCGCCCTTCCGCGAG
GCTTCGGCCAAGCTAACCACGCTGGTGGATGCCGACGCCGAGGCCTTCACCGCCTACCTG
GAAGCAATGAGGCTCCCCAAGAACACACCTGAGGAAAAGGACAGGCGCACGGCGGCCCTA
CAGGAGGGTCTGAGGCGGGCAGTCTCTGTGCCGCTGACGCTGGCGGAGACGGTGGCCTCG
CTGTGGCCGGCGCTGCAGGAACTGGCCCGGTGTGGGAACCTGGCCTGCCGGTCAGACCTC
CAGGTGGCGGCCAAAGCCCTGGAGATGGGCGTGTTTGGCGCATATTTCAACGTGCTCATC
AACCTGAGGGACATCACAGACGAGGCATTTAAGGACCAGATCCACCATCGTGTTTCCAGC
CTCCTGCAGGAAGCCAAGACCCAGGCTGCACTGGTGCTGGACTGCTTGGAGACCCGGCAG
GAGTGA

# Drug_Target_5_General_Function:
Amino acid transport and metabolism

# Drug_Target_5_General_References:
10029623	Lapierre P, Hajoui O, Homberg JC, Alvarez F: Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology. 1999 Mar;116(3):643-9.
10773664	Solans A, Estivill X, de la Luna S: Cloning and characterization of human FTCD on 21q22.3, a candidate gene for glutamate formiminotransferase deficiency. Cytogenet Cell Genet. 2000;88(1-2):43-9.
12815595	Hilton JF, Christensen KE, Watkins D, Raby BA, Renaud Y, de la Luna S, Estivill X, MacKenzie RE, Hudson TJ, Rosenblatt DS: The molecular basis of glutamate formiminotransferase deficiency. Hum Mutat. 2003 Jul;22(1):67-73.

# Drug_Target_5_HGNC_ID:
HGNC:3974

# Drug_Target_5_HPRD_ID:
08430

# Drug_Target_5_ID:
914

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
58927

# Drug_Target_5_Name:
Formimidoyltransferase-cyclodeaminase

# Drug_Target_5_Number_of_Residues:
541

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF04961	FTCD_C
PF07837	FTCD_N

# Drug_Target_5_Protein_Sequence:
>Formimidoyltransferase-cyclodeaminase
MSQLVECVPNFSEGKNQEVIDAISGAITQTPGCVLLDVDAGPSTNRTVYTFVGPPECVVE
GALNAARVASRLIDMSRHQGEHPRMGALDVCPFIPVRGVSVDECVLCAQAFGQRLAEELD
VPVYLYGEAARMDSRRTLPAIRAGEYEALPKKLQQADWAPDFGPSSFVPSWGATATGARK
FLIAFNINLLGTKEQAHRIALNLREQGRGKDQPGRLKKVQGIGWYLDEKNLAQVSTNLLD
FEVTALHTVYEETCREAQELSLPVVGSQLVGLVPLKALLDAAAFYCEKENLFILEEEQRI
RLVVSRLGLDSLCPFSPKERIIEYLVPERGPERGLGSKSLRAFVGEVGARSAAPGGGSVA
AAAAAMGAALGSMVGLMTYGRRQFQSLDTTMRRLIPPFREASAKLTTLVDADAEAFTAYL
EAMRLPKNTPEEKDRRTAALQEGLRRAVSVPLTLAETVASLWPALQELARCGNLACRSDL
QVAAKALEMGVFGAYFNVLINLRDITDEAFKDQIHHRVSSLLQEAKTQAALVLDCLETRQ
E

# Drug_Target_5_Reaction:
5-formimidoyltetrahydrofolate + L-glutamate = tetrahydrofolate + N-formimidoyl-L-glutamate

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Folate-dependent enzyme, that displays both transferase and deaminase activity. Serves to channel one-carbon units from formiminoglutamate to the folate pool

# Drug_Target_5_SwissProt_ID:
O95954

# Drug_Target_5_SwissProt_Name:
FTCD_HUMAN

# Drug_Target_5_Synonyms:
EC 2.1.2.5
EC 4.3.1.4
FTCD
Formimidoyltetrahydrofolate cyclodeaminase
Formiminotransferase- cyclodeaminase
Glutamate formiminotransferase
Glutamate formyltransferase
LCHC1

# Drug_Target_5_Theoretical_pI:
5.45

# Drug_Target_5_Transmembrane_Regions:
None

#END_DRUGCARD DB03256
